scholarly journals Development of a hoRizontal data intEgration classifier for NOn-invasive early diAgnosis of breasT cancEr: the RENOVATE study protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e054256
Author(s):  
Francesco Ravera ◽  
Gabriella Cirmena ◽  
Martina Dameri ◽  
Maurizio Gallo ◽  
Valerio Gaetano Vellone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Data Integration ◽  
Breast Biopsy ◽  
Translational Study ◽  
Non Invasive ◽  
Standard Procedures ◽  
Patient Will ◽  
Diagnostic Biopsy ◽  
Registration Number

IntroductionStandard procedures aimed at the early diagnosis of breast cancer (BC) present suboptimal accuracy and imply the execution of invasive and sometimes unnecessary tissue biopsies. The assessment of circulating biomarkers for diagnostic purposes, together with radiomics, is of great potential in BC management.Methods and analysisThis is a prospective translational study investigating the accuracy of the combined assessment of multiple circulating analytes together with radiomic variables for early BC diagnosis. Up to 750 patients will be recruited at their presentation at the Diagnostic Senology Unit of Ospedale Policlinico San Martino (Genoa, IT) for the execution of a diagnostic biopsy after the detection of a suspect breast lesion (t0). Each recruited patient will be asked to donate peripheral blood and urine before undergoing breast biopsy. Blood and urine samples will also be collected from a cohort of 100 patients with negative mammography. For cases with histological diagnosis of invasive BC, a second sample of blood and urine will be collected after breast surgery. Circulating tumour DNA, cell-free methylated DNA and circulating proteins will be assessed in samples collected at t0 from patients with stage I–IIA BC at surgery together with those collected from patients with histologically confirmed benign lesions of similar size and from healthy controls with negative mammography. These analyses will be combined with radiomic variables extracted with freeware algorithms applied to cases and matched controls for which digital mammography is available. The overall goal of the present study is to develop a horizontal data integration classifier for the early diagnosis of BC.Ethics and disseminationThis research protocol has been approved by Regione Liguria Ethics Committee (reference number: 2019/75, study ID: 4452). Patients will be required to provide written informed consent. Results will be published in international peer-reviewed scientific journals.Trial registration numberNCT04781062.

Decreased serum levels of glycerol-3- phosphate dehydrogenase 1 and monoacylglycerol lipase act as diagnostic biomarkers for breast cancer

2021 ◽  
pp. 1-10
Author(s):  
Kubra Karaosmanoglu Yoneten ◽  
Murat Kasap ◽  
Kazim Yalcin Arga ◽  
Gurler Akpinar ◽  
Nihat Zafer Utkan
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Serum Levels ◽  
Monoacylglycerol Lipase ◽  
Diagnostic Biomarker ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Incidence And Mortality ◽  
Glycerol 3 Phosphate Dehydrogenase ◽  
Early Diagnostic

BACKGROUND: Breast cancer (BC) is one of the most life-threatening cancer types among women. Despite major developments in medical sciences and technologies, the incidence and mortality rates of BC cases are still increasing. One of the reasons for this increase is the absence of an easy to perform early-diagnostic tool. Although there are defined BC biomarkers routinely used for diagnostic and prognostic purposes, none of these biomarkers is useful for early diagnosis. Therefore, early diagnosis of BC remains an important challenge and there is a great need for the early-diagnostic biomarker(s). OBJECTIVE: In this study, we aimed to evaluate the diagnostic and prognostic values of glycerol-3-phosphate dehydrogenase (GPD1) and monoacylglycerol lipase (MAGL) proteins as non-invasive serum biomarkers. METHODS: GPD1 and MAGL serum levels were determined by ELISA for BC patients (n= 100) from five different subtypes, and healthy controls (n= 20), and a comparative analysis was performed to determine statistically significant expression differences among the groups. RESULTS: The results provided evidence that GPD1 acted as a diagnostic biomarker in distinguishing triple-negative breast cancer (TNBC) patients from other subtypes, and MAGL acted as a diagnostic biomarker in distinguishing healthy individuals from BC patients. CONCLUSION: GPD1 and MAGL might be proposed as non-invasive diagnostic biomarkers for BC with high sensitivity and specificity.

scholarly journals Comparison of the Accuracy of Thermography and Mammography in the Detection of Breast Cancer

Breast Care ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. 260-264 ◽  
Author(s):  
Ramesh Omranipour ◽  
Ali Kazemian ◽  
Sadaf Alipour ◽  
Masoume Najafi ◽  
Mansour Alidoosti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Gold Standard ◽  
Breast Biopsy ◽  
Screening Mammography ◽  
Tissue Sampling ◽  
Predictive Values ◽  
Referral Center ◽  
Medical Centers ◽  
Sensitivity Specificity

Background: Benefits and harms of screening mammography have been disputed in recent years. This fact, along with the limitations of mammography as well as its unavailability in all our medical centers, tempted us to evaluate the accuracy of thermography in detecting breast abnormalities. Patients and Methods: All patients who were candidates for breast biopsy were examined by both mammography and thermography before tissue sampling in a referral center between January 2013 and January 2014. We defined sensitivities and specificities, and positive predictive values (PPVs) and negative predictive values (NPVs), of the 2 modalities in comparison with histologic results as the gold standard. Results: 132 patients were included. The median age of all patients was 49.5 ± 10.3 years (range 24-75 years). The sensitivity, specificity, PPV, NPV, and accuracy for mammography were 80.5%, 73.3%, 85.4%, 66.0%, and 76.9%, respectively, whereas for thermography the figures were 81.6%, 57.8%, 78.9%, 61.9%, and 69.7%, respectively. Conclusion: Our study confirms that, at the present time, thermography cannot substitute for mammography for the early diagnosis of breast cancer.

scholarly journals Significance of Some Non-Invasive Biomarkers in the Early Diagnosis and Staging of Egyptian Breast Cancer Patients

2020 ◽  
Vol 21 (11) ◽  
pp. 3279-3284
Author(s):  
Tarek Motawi ◽  
Nadia Zakhary ◽  
Hebatallah Darwish ◽  
Hassan Abdullah ◽  
Samer Tadros
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Non Invasive

scholarly journals Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2848
Author(s):  
Anna Adam-Artigues ◽  
Iris Garrido-Cano ◽  
Juan Antonio Carbonell-Asins ◽  
Ana Lameirinhas ◽  
Soraya Simón ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Principal Component ◽  
Enrichment Analysis ◽  
Pathway Enrichment Analysis ◽  
Roc Curve Analysis ◽  
Diagnostic Biomarkers ◽  
Circulating Micrornas ◽  
Non Invasive ◽  
Parameter Evaluation

The early diagnosis of breast cancer is essential to improve patients’ survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs.

First experience with MRI-guided vacuum aspirated breast biopsy

2020 ◽  
pp. 25-31
Author(s):  
M. L. Mazo ◽  
O. E. Jacobs ◽  
O. S. Puchkova ◽  
M. V. Feldsherov ◽  
E. V. Kondratyev
Keyword(s):  
Breast Cancer ◽  
Breast Augmentation ◽  
Breast Biopsy ◽  
Breast Mri ◽  
Breast Tumors ◽  
High Tech ◽  
X Ray ◽  
Vacuum Aspiration ◽  
Mri Guided ◽  
Aesthetic Breast

The rate of detection of breast cancer by MRI, while other methods of radiological diagnosis are not sufficiently informative, ranges from 5.2 to 26.3 per cent. Suspicious breast tumors of category BI-RADS 4, 5 show morphological image-guided biopsy verification, in particular MRI with contrast. Purpose. To show the possibilities and features of carrying out MRI-guided vacuum breast biopsy, including after aesthetic breast augmentation. Material and methods. A comprehensive X-ray, ultrasound and MRI examination of 54 women aged between 28 and 70 years with different breast tumors was conducted. Of these, five were detected only by breast MRI with contrast, and were morphologically verified by MRI-guided vacuum aspiration biopsy. Results. 14 of the 54 patients with breast mass were diagnosed with breast cancer and 26 were diagnosed with benign diseases. The effectiveness of comprehensive examination and low-invasive high-tech MRI-guided procedures in early refined screening for breast cancer, including after aesthetic breast augmentation, has been demonstrated. MRI-guided vacuum-assisted breast biopsy is a fast, safe and accurate diagnostic method of morphological verification of suspicious breast tumors that do not have X-ray and ultrasound.

Sign in / Sign up

Export Citation Format

Share Document